A more detailed analysis of the safety of cladribine has just been published. Unfortunately, it is too early to comment on the malignancy risk; this will require long-term follow-up and an active post-marketing surveillance programme.
Cook et al. Mult Scler. 2011 Jan 12. [Epub ahead of print]
Disclaimer: As the principal investigator on this study I have an obvious conflict of interest.